



901 California Avenue Palo Alto, CA 94304-1104 Main: 650 • 496-6400 FAX: 650 • 496-1200

**FAX TRANSMITTAL SHEET**NO. OF PAGES (including this page): 4**OFFICIAL**

**TO:** Prema Maria Mertz  
**Art Unit:** 1646  
**FAX:** (703) 872-9306  
**FROM:** Sheela Mohan-Peterson  
**DATE:** April 1, 2004  
**RE:** Docket No.: DX0644KBK  
USSN: 10/083,720  
Filed: 02/28/2002  
Title: Mammalian Cytokine; Related Reagents

**RECEIVED  
CENTRAL FAX CENTER**


APR 01 2004

**Any difficulty with this facsimile, please call:**  
**Melanie Lyons at (650) 496-1183**

Documents attached:

1.	Transmittal	1 page
2.	Response to Restriction Requirement	2 pages

I hereby certify that this correspondence is being facsimile transmitted to the USPTO to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 1, 2004

  
Melanie Lyons

**CONFIDENTIALITY NOTE:** This sheet and/or the document(s) accompanying it contain information belonging to DNAX which is confidential and/or legally privileged. The information is intended only for the use of the person or entity named above. If you have received this fax in error, please immediately notify us by telephone or return Fax.

PTO/SB/21 (03-03)

Approved for use through 04/30/2003. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number


<b>TRANSMITTAL FORM</b> (to be used for all correspondence after initial filing)		Application Number	10/083,720
		Filing Date	02/28/2002
		First Named Inventor	Rene de Waal Malefyt
		Art Unit	1646
		Examiner Name	P. M. Mertz
Total Number of Pages in This Submission	4	Attorney Docket Number	DX0644KBK

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<b>Remarks:</b> 1. Response to Restriction Requirement (2 pages) 2. Fax Transmittal Sheet (1 page)		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Sheela Mohan-Peterson, Reg. No. 41,201 DNAX Research, Inc. 901 California Ave. Palo Alto, CA 94304-1104
Signature	
Date	01-Apr-2004

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below:			
Typed or printed	Melanie Lyons		
Signature		Date	April 1, 2004

This collection of information is required by 37 CFR 4.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Attorney Docket: DX0644KBK

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OFFICIAL

In Re application of:

Rene de WAAL MALEFYT, et al.

Application No.: 10/083,720

Filed: February 28, 2002

For: MAMMALIAN CYTOKINE;  
RELATED REAGENTS

Examiner: P. M. Mertz

Art Unit: 1646

Conf. No.: 1917

RECEIVED  
CENTRAL FAX CENTER

APR 01 2004

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on April 1, 2004.

by:

  
MELANIE LYONS

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Sir:

This is a response to the Restriction Requirement), dated March 18, 2004

1. Restriction Requirement

The Examiner restricted the application into five separate inventions:

- I. Claims 21-25 drawn to a polypeptide of amino acid sequence set forth in SEQ ID NO: 2, classified in class 530, subclass 351.
- II. Claims 26-29 drawn to an antibody which binds to a polypeptide of amino acid set forth in SEQ ID NO: 2, classified in class 530, subclass 387.9.
- III. Claims 30-35 drawn to a polynucleotide encoding a polypeptide of amino acid sequence set forth in SEQ ID NO:2, classified in class 435, subclass 69.5.
- IV. Claims 36, 37, and 39 drawn to a method of treatment by administering an agonist to a polypeptide of amino acid sequence set forth in SEQ ID NO: 2, classified in class and subclass undeterminable.
- V. Claims 36, 38, and 50 drawn to a method of treatment by administering an antagonist to a polypeptide of amino acid sequence set forth in SEQ ID NO: 2, classified in class 424, subclass 139.1.

Applicants provisionally elect Group II, Claims 26-29 whose claims are drawn to an antibody which binds to a polypeptide of amino acid sequence set forth in SEQ ID NO: 2, classified in class 530, subclass 387.9, for example, as discussed in the Office Action.

Applicants will address the issue of inventorship for the elected claims and amend inventorship appropriately if the elected restriction is made final.

Applicants reserve the right to file subsequent applications claiming the non-elected subject matter and do not waive any of their rights or abandon any non-elected subject matter. Since Applicants have fully and completely responded to the Restriction Requirement and have made the required election, this application is now in order for early action.

If the Examiner believes that a telephone conference would aid the prosecution of this case in any way, please call the undersigned.

The Commissioner is hereby authorized to charge the requisite fee to DNAX Deposit Account 04-1239. Please charge any additional fees or credit overpayment to DNAX Deposit Account No. 04-1239.

Respectfully submitted,

Date: 01-Apr-2004

By: Sheela Mohan-Peterson  
Sheela Mohan-Peterson,  
Reg. No. 41,201  
Attorney for Applicants

**Customer No. 028008**  
DNAX Research, Inc.  
901 California Avenue  
Palo Alto, CA 94304-1104  
Telephone (Switchboard): (650) 496-6400  
Telephone No. (Direct): (650) 496-1244  
Facsimile No.: (650) 496-1200